Medtronic up-front payment to Abbott
This article was originally published in The Gray Sheet
First-quarter (ending July 31) one-time charge of $40-45 mil. will be taken as part of the licensing agreement for Abbott's rapamycin analogue ABT-578 and phosphorylcholine polymer coating technology with Medtronic's over-the-wire and rapid-exchange stent delivery systems outside the U.S., Medtronic tells investors June 24. The firms announced the deal May 9 (1"The Gray Sheet" May 13, 2002, p. 8)...
You may also be interested in...
William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.